Welgene Biotech Co.,Ltd. (TPEX:6661)
Taiwan · Delayed Price · Currency is TWD 18.50
-0.15 (-0.80%)
Apr 20, 2026, 10:25 AM CST
Welgene Biotech Revenue
In the year 2025, Welgene Biotech had annual revenue of 375.94M TWD with 16.55% growth. Welgene Biotech had revenue of 97.84M in the quarter ending December 31, 2025, with 11.62% growth.
Revenue
375.94M
Revenue Growth
+16.55%
P/S Ratio
1.15
Revenue / Employee
n/a
Employees
n/a
Market Cap
431.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 375.94M | 53.39M | 16.55% |
| Dec 31, 2024 | 322.55M | 42.00M | 14.97% |
| Dec 31, 2023 | 280.55M | -41.35M | -12.85% |
| Dec 31, 2022 | 321.90M | 9.25M | 2.96% |
| Dec 31, 2021 | 312.65M | -85.45M | -21.46% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| PharmaEssentia | 15.63B |
| EPS Bio Technology | 499.70M |
| Health & Life | 398.05M |
| Visgeneer | 159.76M |
| Taiwan Advanced Nanotech | 154.37M |
| Pharmigene | 149.25M |
| UniPharma | 88.44M |